Genomics

Helix Appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life Sciences

Retrieved on: 
Thursday, March 7, 2024

Helix , the leading population genomics company in the nation, today announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences.

Key Points: 
  • Helix , the leading population genomics company in the nation, today announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences.
  • Kalvaria will oversee partnerships leveraging the unique and growing clinico-genomic datasets of Helix with life sciences customers.
  • Kalvaria also served in leadership roles at Verana Health, Flatiron Health, and Genentech.
  • Helix is committed to partnering with life science companies to leverage real-world clinico-genomic data across the drug development lifecycle.”

Fijoya Raises 8.3M Seed Funding to Pioneer AI-Powered Platform for Employer-Sponsored Healthcare

Retrieved on: 
Thursday, March 7, 2024

Fijoya, a highly personalized platform for employer-sponsored health and wellness services, announced today an $8.3M funding round led by the Venture-Creation fund of Team8.

Key Points: 
  • Fijoya, a highly personalized platform for employer-sponsored health and wellness services, announced today an $8.3M funding round led by the Venture-Creation fund of Team8.
  • Operating at the intersection of fintech and healthcare, Fijoya offers employers a simplified, convenient, and cost-efficient way to offer more flexible health benefits.
  • Given the breadth of employer-sponsored healthcare, Fijoya will initially focus on challenges in the $32 billion point solution vendor market.
  • “This funding will allow Fijoya to expand its platform offerings in pursuit of a broad vision to change the landscape of employer-sponsored healthcare.

India Artificial Intelligence in Drug Discovery Market Research Report 2024: A Lucrative Technology in Healthcare, Filling the Research and Development Gap in Drug Manufacturing - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

The "Artificial Intelligence in Drug Discovery Market in India, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artificial Intelligence in Drug Discovery Market in India, 2024" report has been added to ResearchAndMarkets.com's offering.
  • AI is poised to become a lucrative technology in healthcare, filling the research and development gap in drug manufacturing and enhancing targeted drug production.
  • In India's drug discovery field, AI utilizes advanced computational techniques to expedite various stages of drug development.
  • The stringent regulations and guidelines present a challenge, hindering the seamless integration of AI into India's drug discovery market.

Healthcare and Life Sciences Industries Look to AI and Automation to Boost Growth and Productivity, According to Clari and FiercePharma Study

Retrieved on: 
Wednesday, March 6, 2024

That’s according to the findings of a new Clari-commissioned study by FiercePharma to discover how healthcare and life sciences sales teams are performing in these turbulent times and how sales leaders are positioning for future growth.

Key Points: 
  • That’s according to the findings of a new Clari-commissioned study by FiercePharma to discover how healthcare and life sciences sales teams are performing in these turbulent times and how sales leaders are positioning for future growth.
  • According to the new study1 — “ The State of Sales in Healthcare and Life Sciences ” — sales and revenue leaders are focused on finding ways to accelerate sales productivity and are looking to AI and automation within the next one to three years to drive gains.
  • Within the next 3 years, 67% of executives expect AI and/or sales automation technology to be implemented to drive data accuracy and sales productivity.
  • The platform helped customers save 40% more committed revenue ($9.6B) after customers leveraged the platform for over a year.

NetApp Fights Ransomware in Real-Time with Built-In Artificial Intelligence on Enterprise Storage and Enhanced Cyber-Resiliency Solutions

Retrieved on: 
Tuesday, March 5, 2024

NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time.

Key Points: 
  • NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time.
  • “NetApp is taking an aggressive and proactive approach to protecting our customers’ data against cyber threats using artificial intelligence.
  • We are the first storage vendor to explicitly and financially guarantee our data storage offerings against ransomware,” said Mignona Cote, CSO at NetApp.
  • NetApp Keystone Ransomware Recovery Guarantee extends NetApp’s current Ransomware Recovery Guarantee to our leading storage-as-a-service offering, NetApp Keystone.

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Retrieved on: 
Tuesday, March 5, 2024

This is the second U.S. patent being issued in this patent family.

Key Points: 
  • This is the second U.S. patent being issued in this patent family.
  • Patents in this patent family have also been issued in the European Union, China, India, and Australia.
  • According to the American Heart Association , cardiovascular disease (CVD) claims 2,552 lives daily in the United States, translating to a death every 34 seconds.
  • Heart disease, which includes heart attacks, has been the leading cause of death in the United States for 100 years.

Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision Antimicrobials

Retrieved on: 
Tuesday, March 5, 2024

Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.

Key Points: 
  • Phase Genomics, Inc. , a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.
  • The foundation of this effort rests on Phase Genomics’ proprietary global phage atlas, developed with support from the Gates Foundation and the NIH.
  • Under this project, Phase Genomics will deploy its platform to develop antimicrobial agents that bypass resistance against Campylobacter infections and methanogenic archaea in ruminants that drive global methane emissions.
  • Follow Phase Genomics on X and LinkedIn for the latest news and information.

Team SAMBAI, Yemaachi Biotech, Named as Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024

Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.

Key Points: 
  • Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.
  • “We are confident that this work will be fruitful and will contribute to innovations that will benefit patients globally.
  • We are honored by Team SAMBAI’s belief in our scientific work and impact-driven mission.”
    Inequities in cancer prevention, screening, diagnosis, treatment, and research lead to disparities in cancer incidence and mortality and are a major public health concern.
  • Cancer Grand Challenges is a global funding initiative, co-founded by Cancer Research UK and the National Cancer Institute in the US, that supports a community of diverse, global teams to come together, think differently and take on cancer’s toughest challenges.

Global Monkeypox Diagnostics Market Research Report 2024: Market Analysis & Forecasts 2022-2026 with Executive & Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024

The "Global Monkeypox Diagnostics Market by Assay, Country, Product, and Place, with Executive & Consultant Guides and Market Analysis & Forecasts 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Monkeypox Diagnostics Market by Assay, Country, Product, and Place, with Executive & Consultant Guides and Market Analysis & Forecasts 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • This report forecasts the market size out to 2026.
  • Growth is coming from basic factors but the COVID-19 pandemic has changed the market landscape now and for the foreseeable future.
  • The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.